Dr Reddy’s gets 2 observations from USFDA for formulation plant

PTI New Delhi | Updated on February 28, 2020

Dr Reddy’s Laboratories Ltd

Dr Reddy’s Laboratories on Friday said the US health regulator has issued a Form 483 with two observations after inspecting one of its formulation plants in Hyderabad. In a regulatory filing, the drug major said the US Food and Drug Administration (USFDA) completed audit of its formulations manufacturing plant - 3 at Bachupally, Hyderabad on Friday.

“We have been issued a Form 483 with two observations. We will address them comprehensively within the stipulated timeline,” it added.

As per the USFDA, Form 483 is issued to firm management at the conclusion of an inspection when investigators have observed any conditions that in their judgement may constitute violations of the Food Drug and Cosmetic Act and related Acts.

Dr Reddy’s shares on Friday ended 4.66 per cent up at Rs 2,925.80 apiece on the BSE.

Published on February 28, 2020

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like